Cargando…

Ligand-Based Virtual Screening, Molecular Docking, and Molecular Dynamic Simulations of New β-Estrogen Receptor Activators with Potential for Pharmacological Obesity Treatment

Obesity is a pandemic and a serious health problem in developed and undeveloped countries. Activation of estrogen receptor beta (ERβ) has been shown to promote weight loss without modifying caloric intake, making it an attractive target for developing new drugs against obesity. This work aimed to pr...

Descripción completa

Detalles Bibliográficos
Autores principales: Méndez-Álvarez, Domingo, Torres-Rojas, Maria F., Lara-Ramirez, Edgar E., Marchat, Laurence A., Rivera, Gildardo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10254148/
https://www.ncbi.nlm.nih.gov/pubmed/37298864
http://dx.doi.org/10.3390/molecules28114389
_version_ 1785056573129752576
author Méndez-Álvarez, Domingo
Torres-Rojas, Maria F.
Lara-Ramirez, Edgar E.
Marchat, Laurence A.
Rivera, Gildardo
author_facet Méndez-Álvarez, Domingo
Torres-Rojas, Maria F.
Lara-Ramirez, Edgar E.
Marchat, Laurence A.
Rivera, Gildardo
author_sort Méndez-Álvarez, Domingo
collection PubMed
description Obesity is a pandemic and a serious health problem in developed and undeveloped countries. Activation of estrogen receptor beta (ERβ) has been shown to promote weight loss without modifying caloric intake, making it an attractive target for developing new drugs against obesity. This work aimed to predict new small molecules as potential ERβ activators. A ligand-based virtual screening of the ZINC15, PubChem, and Molport databases by substructure and similarity was carried out using the three-dimensional organization of known ligands as a reference. A molecular docking screening of FDA-approved drugs was also conducted as a repositioning strategy. Finally, selected compounds were evaluated by molecular dynamic simulations. Compounds 1 (−24.27 ± 0.34 kcal/mol), 2 (−23.33 ± 0.3 kcal/mol), and 6 (−29.55 ± 0.51 kcal/mol) showed the best stability on the active site in complex with ERβ with an RMSD < 3.3 Å. RMSF analysis showed that these compounds do not affect the fluctuation of the Cα of ERβ nor the compactness according to the radius of gyration. Finally, an in silico evaluation of ADMET showed they are safe molecules. These results suggest that new ERβ ligands could be promising molecules for obesity control.
format Online
Article
Text
id pubmed-10254148
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-102541482023-06-10 Ligand-Based Virtual Screening, Molecular Docking, and Molecular Dynamic Simulations of New β-Estrogen Receptor Activators with Potential for Pharmacological Obesity Treatment Méndez-Álvarez, Domingo Torres-Rojas, Maria F. Lara-Ramirez, Edgar E. Marchat, Laurence A. Rivera, Gildardo Molecules Article Obesity is a pandemic and a serious health problem in developed and undeveloped countries. Activation of estrogen receptor beta (ERβ) has been shown to promote weight loss without modifying caloric intake, making it an attractive target for developing new drugs against obesity. This work aimed to predict new small molecules as potential ERβ activators. A ligand-based virtual screening of the ZINC15, PubChem, and Molport databases by substructure and similarity was carried out using the three-dimensional organization of known ligands as a reference. A molecular docking screening of FDA-approved drugs was also conducted as a repositioning strategy. Finally, selected compounds were evaluated by molecular dynamic simulations. Compounds 1 (−24.27 ± 0.34 kcal/mol), 2 (−23.33 ± 0.3 kcal/mol), and 6 (−29.55 ± 0.51 kcal/mol) showed the best stability on the active site in complex with ERβ with an RMSD < 3.3 Å. RMSF analysis showed that these compounds do not affect the fluctuation of the Cα of ERβ nor the compactness according to the radius of gyration. Finally, an in silico evaluation of ADMET showed they are safe molecules. These results suggest that new ERβ ligands could be promising molecules for obesity control. MDPI 2023-05-27 /pmc/articles/PMC10254148/ /pubmed/37298864 http://dx.doi.org/10.3390/molecules28114389 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Méndez-Álvarez, Domingo
Torres-Rojas, Maria F.
Lara-Ramirez, Edgar E.
Marchat, Laurence A.
Rivera, Gildardo
Ligand-Based Virtual Screening, Molecular Docking, and Molecular Dynamic Simulations of New β-Estrogen Receptor Activators with Potential for Pharmacological Obesity Treatment
title Ligand-Based Virtual Screening, Molecular Docking, and Molecular Dynamic Simulations of New β-Estrogen Receptor Activators with Potential for Pharmacological Obesity Treatment
title_full Ligand-Based Virtual Screening, Molecular Docking, and Molecular Dynamic Simulations of New β-Estrogen Receptor Activators with Potential for Pharmacological Obesity Treatment
title_fullStr Ligand-Based Virtual Screening, Molecular Docking, and Molecular Dynamic Simulations of New β-Estrogen Receptor Activators with Potential for Pharmacological Obesity Treatment
title_full_unstemmed Ligand-Based Virtual Screening, Molecular Docking, and Molecular Dynamic Simulations of New β-Estrogen Receptor Activators with Potential for Pharmacological Obesity Treatment
title_short Ligand-Based Virtual Screening, Molecular Docking, and Molecular Dynamic Simulations of New β-Estrogen Receptor Activators with Potential for Pharmacological Obesity Treatment
title_sort ligand-based virtual screening, molecular docking, and molecular dynamic simulations of new β-estrogen receptor activators with potential for pharmacological obesity treatment
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10254148/
https://www.ncbi.nlm.nih.gov/pubmed/37298864
http://dx.doi.org/10.3390/molecules28114389
work_keys_str_mv AT mendezalvarezdomingo ligandbasedvirtualscreeningmoleculardockingandmoleculardynamicsimulationsofnewbestrogenreceptoractivatorswithpotentialforpharmacologicalobesitytreatment
AT torresrojasmariaf ligandbasedvirtualscreeningmoleculardockingandmoleculardynamicsimulationsofnewbestrogenreceptoractivatorswithpotentialforpharmacologicalobesitytreatment
AT lararamirezedgare ligandbasedvirtualscreeningmoleculardockingandmoleculardynamicsimulationsofnewbestrogenreceptoractivatorswithpotentialforpharmacologicalobesitytreatment
AT marchatlaurencea ligandbasedvirtualscreeningmoleculardockingandmoleculardynamicsimulationsofnewbestrogenreceptoractivatorswithpotentialforpharmacologicalobesitytreatment
AT riveragildardo ligandbasedvirtualscreeningmoleculardockingandmoleculardynamicsimulationsofnewbestrogenreceptoractivatorswithpotentialforpharmacologicalobesitytreatment